Page 451 - Read Online

Dave et al. Nibrin expression in OSCC

patients strong Nibrin expression was associated the head and neck. Semin Oncol 2004;31:755-68.
significantly with shorter overall survival compared 8. Scully C, Field JK, Tanzawa H. Genetic aberrations in oral or head
with weak expression. Ehlers et al. have also found and neck squamous cell carcinoma 3: clinicopathological applications.
[33]
that in uveal melanoma, the 6-year survival was 100% 9. Oral Oncol 2000;36:404-13.
Nagpal JK, Das BR. Oral cancer: reviewing the present understanding
for the low NBS1 group and 22% for the high NBS1 of its molecular mechanisms and exploring the future directions for its
group (P = 0.01). In the breast carcinoma, patients effective management. Oral Oncol 2003;39:213-21.
with NBS1-aberrant tumors seemed to have poorer 10. Nagai MA. Genetic alterations in head and neck squamous cell
survival than the patients with NBS1 normal tumors. carcinomas. Braz J Med Biol Res 1999;32:897-904.
This indicates that the NBS1 deficiency predicts poor 11. Vilenchik MM, Knudson AG Jr. Inverse radiation dose-rate effects on
survival of the breast carcinoma patients. [34] somatic and germ-line mutations and DNA damage rates. Proc Natl
Acad Sci U S A 2000;97:5381-6.
In conclusion, our study discovered that a Nibrin protein 12. Arnott RD, Bernstein PL. What risk premium is “normal”? Financial
Analyst J 2002;58:64-85.
expression is significant in lower tumor size and early 13. Petrini JH. The Mre11 complex and ATM: collaborating to navigate S
stage disease in OSCC indicating its role in early event phase. Curr Opin Cell Biol 2000;12:293-6.
of disease progression. Further, high incidence of 14. Karran P. DNA double strand break repair in mammalian cells. Curr
disease relapse was found to be present in early stage Opin Genet Dev 2000;10:144-50.
patients with strong Nibrin expression. Thus, it could 15. D’Amours D, Jackson SP. The Mre11 complex: at the crossroads
be used as a favorable prognostic factor in developing of DNA repair and checkpoint signaling. Nat Rev Mol Cell Biol
disease recurrence in patients with early stage 2002;3:317-27.
disease. Further, among various cancers, the different 16. Cerosaletti KM, Lange E, Stringham HM, Weemaes CM, Smeets D,
Sölder B, Belohradsky BH, Taylor AM, Karnes P, Elliott A, Komatsu
patterns of the Nibrin expression have observed which K, Gatti RA, Boehnke M, Concannon P. Fine localization of the
indicates that the expression of Nibrin is important in Nijmegen breakage syndrome gene to 8q21: evidence for a common
cancer development and progression with cancer cell founder haplotype. Am J Hum Genet 1998;63:125-34.
type specificity, although the mechanism behind it is 17. Nelms BE, Maser RS, MacKay JF, Lagally MG, Petrini JH. In situ
unclear. visualization of DNA double-strand break repair in human fibroblasts.
Science 1998;280:590-2.
Financial support and sponsorship 18. Pandita TK, Pathak S, Geard CR. Chromosome end associations,
This work was supported by the Gujarat Cancer Society telomeres and telomerase activity in ataxia telangiectasia cells.
Cytogenet Cell Genet 1995;71:86-93.
and the Gujarat Cancer and Research Institute. 19. Metcalfe JA, Parkhill J, Campbell L, Stacey M, Biggs P, Byrd PJ,
Taylor AM. Accelerated telomere shortening in ataxia telangiectasia.
Conflicts of interest Nat Genet 1996;13:350-3.
There are no conflicts of interest. 20. Lim DS, Kim ST, Xu B, Maser RS, Lin J, Petrini JH, Kastan MB.
ATM phosphorylates p95/nbs1 in an S-phase checkpoint pathway.
Patient consent Nature 2000;404:613-7.
Patient consent was obtained from the patients. 21. Zhao S, Weng YC, Yuan SS, Lin YT, Hsu HC, Lin SC, Gerbino E,
Song MH, Zdzienicka MZ, Gatti RA, Shay JW, Ziv Y, Shiloh Y, Lee
Ethics approval EY. Functional link between ataxia-telangiectasia and Nijmegen
breakage syndrome gene products. Nature 2000;405:474-7.
Ethics approval was obtained from the Gujarat 22. Wu X, Ranganathan V, Weisman DS, Heine WF, Ciccone DN, O’
Cancer and Research Institute. Neill TB, Crick KE, Pierce KA, Lane WS, Rathbun G, Livingston
DM, Weaver DT. ATM phosphorylation of Nijmegen breakage
REFERENCES syndrome protein is required in a DNA damage response. Nature
2000;405:477-82.
1. Bettendorf O, Piffkò J, Bànkfalvi A. Prognostic and predictive factors 23. Stumm M, von Ruskowsky A, Siebert R, Harder S, Varon R, Wieacker
in oral squamous cell cancer: important tools for planning individual P, Schlegelberger B. No evidence for deletions of the NBS1 gene in
therapy? Oral Oncol 2004;40:110-9. lymphomas. Cancer Genet Cytogenet 2001;26:60-2.
2. Nagler RM. Molecular aspects of oral cancer. Anticancer Res 24. Varon R, Reis A, Henze G, von Einsiedel HG, Sperling K, Seeger
2002;22:2977-80. K. Mutations in the Nijmegen Breakage syndrome gene (NBS1)
3. Zbären P, Lehmann W. Frequency and sites of distant metastases in in childhood acute lymphoblastic leukemia (ALL). Cancer Res
head and neck squamous cell carcinoma. An analysis of 101 cases at 2001;61:3570-2.
autopsy. Arch Otolaryngol Head Neck Surg 1987;113:762-4. 25. Plisiecka-Halasa J, Dansonka-Mieszkowska A, Rembiszewska A,
4. Neville BW, Day TA. Oral cancer and precancerous lesions. CA Bidziński M, Steffen J, Kupryjańczyk J. Nijmegen breakage syndrome
Cancer J Clin 2002;52:195-215. gene (NBS1) alterations and its protein (nibrin) expression in human
5. Feller L, Lemmer J. Oral squamous cell carcinoma: epidemiology, ovarian tumors. Ann Hum Genet 2002;66:353-9.
clinical presentation and treatment. J Cancer Ther 2012;3:263-8. 26. Wilda M, Demuth I, Concannon P, Sperling K, Hameister H.
6. Facompre N, Nakagawa H, Herlyn M, Basu D. Stem-like cells and Expression pattern of the Nijmegen breakage syndrome gene, Nbs1,
therapy resistance in squamous cell carcinomas. Adv Pharmacol during murine development. Hum Mol Genet 2000;9:1739-44.
2012;65:235-65. 27. Featherstone C, Jackson SP. DNA repair: The Nijmegen breakage
7. Cohen EE. Novel therapeutic targets in squamous cell carcinoma of syndrome protein. Curr Biol 1998;8:622-5.
Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ November 25, 2016 441